Clinical improvements were achieved and maintained for up to 3 years among bDMARD-naïve patients with PsA who received bimekizumab.

Treatment with open-label tofacitinib improved disease activity among patients with sJIA but did not significantly prolong the time to flare compared with placebo.

Patients with systemic vasculitides vs healthy controls were associated with elevated risks for both osteoporosis and fragility fractures.

Mortality and rates of respiratory hospitalization were similar among patients with RA-ILD initiating various non-TNF inhibitor b/tsDMARDs.